Related Experiment Video
Updated: Apr 12, 2026
Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening
Published on: July 18, 2012
Activity of fluconazole and its Cu(II) complex towards Candida species
Adam Ząbek1, Justyna Nagaj2, Agnieszka Grabowiecka1
1Department of Chemistry, Wroclaw University of Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland.
Abstract:
Candida species, although they are present as commensal organisms in the digestive tract of healthy individuals, can produce a broad spectrum of serious illnesses in compromised hosts. Fluconazole, a water-soluble triazole with bioavailability greater than 90 %, has been extensively used to treat a wide range of Candida infections. However, a growing resistance of microorganisms in the treatment leads to the discovery of new drugs or modifications of existing ones. The aim of the present study was to investigate whether coordination of Cu(II) ions to fluconazole affects its antifungal activity. The in vitro susceptibility tests and antifungal studies were performed with two Candida spp.: Candidaglabrata and Candida albicans. Overall, 34 strains of the former and 16 strains of the latter were treated with fluconazole, its Cu(II) complex and free Cu(II) ions. The obtained MIC values in 16 cases of the C. glabrata and in 5 cases of the C. albicans were lower for the complex in comparison to the drug. This implies that the complex is more effective against particular strains than the parent drug. The most significant improvement in the complex drug efficacy was observed for fluconazole-resistant species.
Insights
Researchers explored copper(II) complexation with fluconazole to combat antifungal resistance. The new fluconazole-copper(II) complex demonstrated enhanced efficacy against resistant Candida strains, offering a promising alternative for treating challenging fungal infections.
Area of Science:
- Medical Mycology
- Medicinal Chemistry
- Antimicrobial Drug Discovery
Background:
- Candida species are opportunistic pathogens causing serious infections in immunocompromised individuals.
- Fluconazole is a widely used antifungal agent, but rising resistance necessitates new therapeutic strategies.
- Metal-ion complexation is a potential approach to enhance drug efficacy and overcome resistance mechanisms.
Purpose of the Study:
- To synthesize and evaluate the antifungal activity of a copper(II)-fluconazole complex.
- To determine if complexation with Cu(II) ions improves fluconazole's efficacy against Candida species.
- To assess the complex's effectiveness, particularly against fluconazole-resistant strains.
Main Methods:
- In vitro susceptibility testing was performed on 34 strains of Candida glabrata and 16 strains of Candida albicans.
- Minimum Inhibitory Concentration (MIC) values were determined for fluconazole, the Cu(II)-fluconazole complex, and free Cu(II) ions.
- Comparative analysis of antifungal activity between the parent drug and its metal complex.
Main Results:
- The Cu(II)-fluconazole complex exhibited lower MIC values compared to fluconazole alone in 16 C. glabrata and 5 C. albicans strains.
- The complex demonstrated superior antifungal activity against specific strains of both Candida species tested.
- A notable enhancement in efficacy was observed for the complex when tested against fluconazole-resistant isolates.
Conclusions:
- Coordination of Cu(II) ions to fluconazole can significantly enhance its antifungal potency.
- The Cu(II)-fluconazole complex represents a promising therapeutic candidate for treating infections caused by resistant Candida strains.
- This study highlights the potential of metal-drug complexes in overcoming antifungal drug resistance.
